Cargando…

Chromatin states define tumor-specific T cell dysfunction and reprogramming

Tumour-specific CD8 T cells in solid tumours are dysfunctional, allowing tumours to progress. The epigenetic regulation of T cell dysfunction and therapeutic reprogrammability (for example, to immune checkpoint blockade) is not well understood. Here we show that T cells in mouse tumours differentiat...

Descripción completa

Detalles Bibliográficos
Autores principales: Philip, Mary, Fairchild, Lauren, Sun, Liping, Horste, Ellen L., Camara, Steven, Shakiba, Mojdeh, Scott, Andrew C., Viale, Agnes, Lauer, Peter, Merghoub, Taha, Hellmann, Matthew D., Wolchok, Jedd D., Leslie, Christina S., Schietinger, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693219/
https://www.ncbi.nlm.nih.gov/pubmed/28514453
http://dx.doi.org/10.1038/nature22367
_version_ 1783279914416340992
author Philip, Mary
Fairchild, Lauren
Sun, Liping
Horste, Ellen L.
Camara, Steven
Shakiba, Mojdeh
Scott, Andrew C.
Viale, Agnes
Lauer, Peter
Merghoub, Taha
Hellmann, Matthew D.
Wolchok, Jedd D.
Leslie, Christina S.
Schietinger, Andrea
author_facet Philip, Mary
Fairchild, Lauren
Sun, Liping
Horste, Ellen L.
Camara, Steven
Shakiba, Mojdeh
Scott, Andrew C.
Viale, Agnes
Lauer, Peter
Merghoub, Taha
Hellmann, Matthew D.
Wolchok, Jedd D.
Leslie, Christina S.
Schietinger, Andrea
author_sort Philip, Mary
collection PubMed
description Tumour-specific CD8 T cells in solid tumours are dysfunctional, allowing tumours to progress. The epigenetic regulation of T cell dysfunction and therapeutic reprogrammability (for example, to immune checkpoint blockade) is not well understood. Here we show that T cells in mouse tumours differentiate through two discrete chromatin states: a plastic dysfunctional state from which T cells can be rescued, and a fixed dysfunctional state in which the cells are resistant to reprogramming. We identified surface markers associated with each chromatin state that distinguished reprogrammable from non-reprogrammable PD1(hi) dysfunctional T cells within heterogeneous T cell populations from tumours in mice; these surface markers were also expressed on human PD1(hi) tumour-infiltrating CD8 T cells. Our study has important implications for cancer immunotherapy as we define key transcription factors and epigenetic programs underlying T cell dysfunction and surface markers that predict therapeutic reprogrammability.
format Online
Article
Text
id pubmed-5693219
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-56932192017-11-20 Chromatin states define tumor-specific T cell dysfunction and reprogramming Philip, Mary Fairchild, Lauren Sun, Liping Horste, Ellen L. Camara, Steven Shakiba, Mojdeh Scott, Andrew C. Viale, Agnes Lauer, Peter Merghoub, Taha Hellmann, Matthew D. Wolchok, Jedd D. Leslie, Christina S. Schietinger, Andrea Nature Article Tumour-specific CD8 T cells in solid tumours are dysfunctional, allowing tumours to progress. The epigenetic regulation of T cell dysfunction and therapeutic reprogrammability (for example, to immune checkpoint blockade) is not well understood. Here we show that T cells in mouse tumours differentiate through two discrete chromatin states: a plastic dysfunctional state from which T cells can be rescued, and a fixed dysfunctional state in which the cells are resistant to reprogramming. We identified surface markers associated with each chromatin state that distinguished reprogrammable from non-reprogrammable PD1(hi) dysfunctional T cells within heterogeneous T cell populations from tumours in mice; these surface markers were also expressed on human PD1(hi) tumour-infiltrating CD8 T cells. Our study has important implications for cancer immunotherapy as we define key transcription factors and epigenetic programs underlying T cell dysfunction and surface markers that predict therapeutic reprogrammability. 2017-05-17 2017-05-25 /pmc/articles/PMC5693219/ /pubmed/28514453 http://dx.doi.org/10.1038/nature22367 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Philip, Mary
Fairchild, Lauren
Sun, Liping
Horste, Ellen L.
Camara, Steven
Shakiba, Mojdeh
Scott, Andrew C.
Viale, Agnes
Lauer, Peter
Merghoub, Taha
Hellmann, Matthew D.
Wolchok, Jedd D.
Leslie, Christina S.
Schietinger, Andrea
Chromatin states define tumor-specific T cell dysfunction and reprogramming
title Chromatin states define tumor-specific T cell dysfunction and reprogramming
title_full Chromatin states define tumor-specific T cell dysfunction and reprogramming
title_fullStr Chromatin states define tumor-specific T cell dysfunction and reprogramming
title_full_unstemmed Chromatin states define tumor-specific T cell dysfunction and reprogramming
title_short Chromatin states define tumor-specific T cell dysfunction and reprogramming
title_sort chromatin states define tumor-specific t cell dysfunction and reprogramming
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693219/
https://www.ncbi.nlm.nih.gov/pubmed/28514453
http://dx.doi.org/10.1038/nature22367
work_keys_str_mv AT philipmary chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT fairchildlauren chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT sunliping chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT horsteellenl chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT camarasteven chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT shakibamojdeh chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT scottandrewc chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT vialeagnes chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT lauerpeter chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT merghoubtaha chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT hellmannmatthewd chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT wolchokjeddd chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT lesliechristinas chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming
AT schietingerandrea chromatinstatesdefinetumorspecifictcelldysfunctionandreprogramming